Jeff Yass’s Oncolytics Biotech ONCY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-134,129
Closed -$127K – 14254
2026
Q2
$127K Buy
134,129
+92,806
+225% +$86K ﹤0.01% 12315
2026
Q1
$35.1K Buy
+41,323
New +$41.1K ﹤0.01% 12725
2025
Q2
– Sell
-19,994
Closed -$11K – 13425
2025
Q1
$11K Buy
+19,994
New +$14.6K ﹤0.01% 12208
2024
Q1
– Sell
-30,306
Closed -$40.9K – 12999
2023
Q4
$40.9K Buy
+30,306
New +$47.4K ﹤0.01% 11791
2022
Q3
– Sell
-71,167
Closed -$70K – 13859
2022
Q2
$70K Buy
+71,167
New +$86.5K ﹤0.01% 11770
2022
Q1
– Sell
-10,059
Closed -$14K – 13695
2021
Q4
$14K Buy
+10,059
New +$18.6K ﹤0.01% 12883
2019
Q2
– Sell
-10,143
Closed -$19K – 10650
2019
Q1
$19K Sell
10,143
-4,424
-30% -$8.96K ﹤0.01% 8597
2018
Q4
$26K Buy
+14,567
New +$39.5K ﹤0.01% 8638

Other funds holding ONCY

Jeff Yass's ONCY Position: Q3 2026 in Review

Jeff Yass sold out of Oncolytics Biotech (ONCY) in Q3 2026, closing a stake of 134,129 shares — an estimated $127K sold.

Jeff Yass first reported a position in ONCY in Q4 2018 and held it in 8 quarters. The position peaked at $127K in Q2 2026. 77 funds tracked by Wall St. Rank hold ONCY as of Q3 2026.

  • Jeff Yass reported no remaining Oncolytics Biotech position as of Q3 2026 after selling out during the quarter.
  • Jeff Yass sold 134,129 Oncolytics Biotech shares in Q3 2026, an estimated $127K.
  • Jeff Yass first reported a position in Oncolytics Biotech in Q4 2018 and held it in 8 quarters.
  • Jeff Yass's Oncolytics Biotech position peaked at $127K in Q2 2026.
  • 77 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.